Axsome Therapeutics, Inc.
Informe acción DB:19X
Capitalización de mercado: €4.1b
Axsome Therapeutics Crecimiento futuro
Future controles de criterios 6/6 Se prevé un crecimiento anual de los beneficios y los ingresos de Axsome Therapeutics de 69.2% y 38.4% por año respectivamente. Se prevé que el BPA crezca en un 68.6% al año. Se espera que la rentabilidad financiera sea de 126.2% en 3 años.
Información clave
69.2%
Tasa de crecimiento de los beneficios
68.6%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals 17.9% Tasa de crecimiento de los ingresos 38.4% Rentabilidad financiera futura 126.2% Cobertura de analistas Good
Última actualización 22 Oct 2024
Actualizaciones recientes sobre el crecimiento futuro
Forecast breakeven date pushed back to 2026 May 07
Forecast to breakeven in 2025 Feb 20
Forecast to breakeven in 2025 Nov 08
Forecast to breakeven in 2025 Apr 27
Forecast to breakeven in 2025 Dec 31
No longer forecast to breakeven Oct 20
Mostrar todas las actualizaciones
Axsome Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 15
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine Sep 05
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc Aug 21
New minor risk - Share price stability Aug 07
Second quarter 2024 earnings released: US$1.67 loss per share (vs US$1.54 loss in 2Q 2023) Aug 06
Axsome Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 12
Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd Jun 06
Forecast breakeven date pushed back to 2026 May 07
First quarter 2024 earnings released: US$1.44 loss per share (vs US$0.26 loss in 1Q 2023) May 06
Axsome Therapeutics, Inc., Annual General Meeting, Jun 07, 2024 Apr 28
Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 11
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder Apr 02 Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder Mar 19
Full year 2023 earnings released: US$5.27 loss per share (vs US$4.60 loss in FY 2022) Feb 22
Forecast to breakeven in 2025 Feb 20
Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024 Jan 24
Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers Nov 17
Forecast to breakeven in 2025 Nov 08
Third quarter 2023 earnings released: US$1.32 loss per share (vs US$1.08 loss in 3Q 2022) Nov 07
Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference Oct 25 Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors Oct 12
Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 11
Axsome Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 13
Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (Adhd) in Adults Jul 08 Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million. Jun 30
Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million. Jun 29
Axsome Therapeutics, Inc. to Present New Sunosi Data at Sleep 2023 Jun 02
Forecast to breakeven in 2025 Apr 27
Axsome Therapeutics, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 01
Forecast to breakeven in 2025 Dec 31
Axsome Therapeutics Presents New Data from the Evolve Open-Label Trial Demonstrating Effects of Auvelity® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder At the American College of Neuropsychopharmacology (Acnp) 2022 Annual Meeting Dec 08
Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation Nov 29
Insufficient new directors Nov 16
Axsome Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 22
Axsome Therapeutics, Inc. Announces Availability of Auvelity, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults Oct 21
No longer forecast to breakeven Oct 20
Axsome Therapeutics, Inc. Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the Sharp Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Oct 04
Axsome Therapeutics, Inc. Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting Sep 30
Axsome Therapeutics, Inc. Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation Sep 09
Forecast to breakeven in 2024 Sep 08
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research Sep 08
Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor Sep 02
Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults Aug 20
No longer forecast to breakeven Aug 11
Axsome Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 29
Axsome Therapeutics, Inc. Receives from the U.S. Food and Drug Administration Jun 28
The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 12, 2022 Jun 09
Axsome Therapeutics Presents New Data from the Gemini Trial Demonstrating Efficacy of Axs-05 on Anhedonia in Patients with Major Depressive Disorder Jun 04
Axsome Therapeutics, Inc. Presents New Data from the Gemini Trial Demonstrating Efficacy of Axs 05 on Anhedonia in Patients with Major Depressive Disorder Jun 03 Axsome Therapeutics Announces Positive Results of the Evolve Trial of AXS-05 in Major Depressive Disorder
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in the Journal of Clinical Psychiatry Jun 01
Axsome Therapeutics Announces Publication of Pivotal Ascend Phase 2 Trial of AXS-05 in Major Depressive Disorder in the American Journal of Psychiatry May 19
Pomerantz Law Firm Announces the Filing of A Class Action Against Axsome Therapeutics, Inc. and Certain Officers May 14
No longer forecast to breakeven May 03
Insufficient new directors Apr 27 Axsome Therapeutics, Inc. to Report Q1, 2022 Results on May 02, 2022
Axsome Therapeutics, Inc., Annual General Meeting, Jun 03, 2022 Apr 23
Axsome Therapeutics, Inc. (NasdaqGM:AXSM) agreed to acquire Sunosi® from Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) for $53 million. Mar 29
Axsome Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 16
Axsome and Baudax Bio, Inc. Enters into Litigation Discontinuance Agreement Feb 08
Forecast to breakeven in 2024 Jan 01
Independent Lead Director recently bought €130k worth of stock Nov 24
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy Sep 19
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine Sep 15
Axsome Therapeutics, Inc. Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder Aug 24
No longer forecast to breakeven Aug 10
Axsome Therapeutics, Inc. Notifies the U.S. Food and Drug Administration Rescinding the Company’s Breakthrough Therapy Designation for Its AXS-12 Product Candidate for the Treatment of Cataplexy in Narcolepsy Jul 15
Axsome Therapeutics, Inc. Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia Jun 16
Axsome Therapeutics, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder Apr 27
New 90-day low: €56.14 Feb 23
Axsome Therapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021 Feb 17
Axsome Therapeutics, Inc Announces Results from the Company's MOVEMENT trial of AXS-07 Jan 02 Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
New 90-day high: €69.76 Dec 24
Axsome Therapeutics, Inc. Announces Positive Results from the Comet-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation Dec 10
Axsome Therapeutics, Inc. Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression Dec 03
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder Dec 02
New 90-day low: €55.69 Nov 07
Axsome Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
New 90-day low: €57.79 Oct 22
Axsome Therapeutics, Inc. announced that it expects to receive $225 million in funding from Hercules Capital, Inc., and other investors Sep 30
Axsome Therapeutics, Inc. Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Sep 26
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting Sep 22
New 90-day low - €60.36 Sep 03
Axsome Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Jul 31
New 90-day low - €62.70 Jul 30
Previsiones de crecimiento de beneficios e ingresos DB:19X - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions) Fecha Ingresos Beneficios Flujo de caja libre Flujo de caja operativo Núm. de analistas medio 12/31/2026 1,041 147 79 219 12 12/31/2025 632 -110 -116 -68 17 12/31/2024 373 -274 -134 -204 17 6/30/2024 291 -309 -168 -167 N/A 3/31/2024 251 -296 -193 -193 N/A 12/31/2023 271 -239 -146 -145 N/A 9/30/2023 223 -202 -143 -142 N/A 6/30/2023 182 -184 -112 -111 N/A 3/31/2023 145 -159 -90 -90 N/A 12/31/2022 50 -187 -117 -117 N/A 9/30/2022 26 -160 -118 -118 N/A 6/30/2022 9 -150 -123 -122 N/A 3/31/2022 N/A -141 -114 -114 N/A 12/31/2021 N/A -130 -109 -108 N/A 9/30/2021 N/A -126 -100 -100 N/A 6/30/2021 N/A -114 -89 -89 N/A 3/31/2021 N/A -100 -82 -82 N/A 12/31/2020 N/A -103 -79 -78 N/A 9/30/2020 N/A -99 -75 -75 N/A 6/30/2020 N/A -95 -70 -70 N/A 3/31/2020 N/A -90 -60 -60 N/A 12/31/2019 N/A -68 -46 -46 N/A 9/30/2019 N/A -53 -39 -39 N/A 6/30/2019 N/A -42 -34 -34 N/A 3/31/2019 N/A -37 -33 -33 N/A 12/31/2018 N/A -31 -30 -30 N/A 9/30/2018 N/A -29 -27 -27 N/A 6/30/2018 N/A -27 -27 -27 N/A 3/31/2018 N/A -26 N/A -27 N/A 12/31/2017 N/A -29 N/A -26 N/A 9/30/2017 N/A -29 N/A -27 N/A 6/30/2017 N/A -30 N/A -26 N/A 3/31/2017 N/A -29 N/A -24 N/A 12/31/2016 N/A -27 N/A -21 N/A 9/30/2016 N/A -23 N/A -16 N/A 6/30/2016 N/A -21 N/A -13 N/A 3/31/2016 N/A -16 N/A -10 N/A 12/31/2015 N/A -12 N/A -7 N/A 9/30/2015 N/A -10 N/A -7 N/A 6/30/2015 N/A -6 N/A -6 N/A 3/31/2015 N/A -6 N/A -5 N/A 12/31/2014 N/A -6 N/A -5 N/A
Mostrar más
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que 19X sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1%).
Beneficios vs. Mercado: Se prevé que 19X sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que 19X sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (38.4% al año) de 19X crezcan más rápidamente que los del mercado German (5.5% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (38.4% al año) de 19X crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de 19X sea muy elevada dentro de 3 años (126.2%).
Descubre empresas en crecimiento Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}